On July 2, HJ Science-B rose 8.75% in regular trading, trading at HK$39.4 per share, with turnover of HK$5.60 million.
HJ Science was co-founded by multiple Ph.D. holders and is primarily engaged in the research, development, and production of innovative drugs targeting oncology, autoimmune diseases, and metabolic diseases.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)